Novelmed Therapeutics

This study tests a new drug called NM8074 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are currently taking Soliris. The goal is to see if NM8074 is safe and works better at controlling the disease. Participants will receive NM8074 while doctors monitor side ef…

This early-phase study tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease. The main goal is to see if the drug can lower protein in the urine, a sign of kidney damage, after 99 days. Participants must have had a kidney biopsy confirming the disease and…

This study tests a new medicine called NM8074 in 12 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS). The goal is to see if the drug can stop abnormal blood clotting and improve kidney function. Participants will receive the drug through a vein, and res…

This early-stage trial tests a new drug, NM8074, in 18 adults with C3 glomerulopathy, a rare kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can reduce protein leakage into urine, a sign of kidney damage. Participants will re…